TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00627679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAP0010 low dose
Description: Treatment B = a single dose of MAP0010 (unit dose budesonide) low dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAP0010 low dose
Description: Treatment B = a single dose of MAP0010 (unit dose budesonide) low dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAP0010 low dose
Description: Treatment B = a single dose of MAP0010 (unit dose budesonide) low dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAP0010 low dose
Description: Treatment B = a single dose of MAP0010 (unit dose budesonide) low dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAP0010 intermediate dose
Description: Treatment C = a single dose of MAP0010 (unit dose budesonide) intermediate dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
Study: NCT02391714

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Description: Given in a fixed dose ratio of 50% nitrous oxide/50% oxygen via nasal mask.
Study: NCT03890835

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MTA Pulpotomy.
Description: Pulpotomy using MTA.
Study: NCT00538499

Intervention type: DRUG
Group type: OTHER
Intervention: Fentanyl citrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine hydrocloride

Intervention type: PROCEDURE
Group type: OTHER
Intervention: videothoracoscopy
Study: NCT03890835

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biodentine Pulpotomy
Description: Pulpotomy using Biodentine
Study: NCT02724423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL-1
Study: NCT00627679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAP0010 intermediate dose
Description: Treatment C = a single dose of MAP0010 (unit dose budesonide) intermediate dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAP0010 intermediate dose
Description: Treatment C = a single dose of MAP0010 (unit dose budesonide) intermediate dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAP0010 intermediate dose
Description: Treatment C = a single dose of MAP0010 (unit dose budesonide) intermediate dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAP0010 high dose
Description: Treatment D = a single dose of MAP0010 (unit dose budesonide) high dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAP0010 high dose
Description: Treatment D = a single dose of MAP0010 (unit dose budesonide) high dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
Study: NCT00807040

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mitral Valve Repair with Annuloplasty
Description: The annuloplasty ring will be chosen by the surgeon. The ring is sized to the anterior leaflet and intertrigonal distance. A semi-rigid or rigid annuloplasty ring will be used, and if tethering is present, a subvalvar procedure will be performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mitral Valve Replacement
Description: Mitral valve replacement will include complete preservation of the subvalvar apparatus. The technique of preservation, choice of prosthetic valve, and technique of suture placement will be dependent on the surgeon's preference. The prosthetic valve will be tested for paravalvular leaks by using the left ventricular saline infusion test.
Study: NCT00833391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: open label
Description: This is an open-label, randomized, single-dose, five-period, crossover study. All subjects will receive GSK1838262.
Study: NCT00627679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAP0010 high dose
Description: Treatment D = a single dose of MAP0010 (unit dose budesonide) high dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAP0010 high dose
Description: Treatment D = a single dose of MAP0010 (unit dose budesonide) high dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
Study: NCT04260815

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct-current stimulation (tDCS)
Description: Transcranial direct-current stimulation is a non-invasive brain stimulation method that can modify spontaneous cortical activity in targeted brain regions. Anodal tDCS delivered through a positively charged electrode has been found to increase cortical excitability in a targeted brain region. Application of tDCS has been found to improve language production in healthy and brain-injured speakers.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct-current stimulation (tDCS)
Description: Transcranial direct-current stimulation is a non-invasive brain stimulation method that can modify spontaneous cortical activity in targeted brain regions. Anodal tDCS delivered through a positively charged electrode has been found to increase cortical excitability in a targeted brain region. Application of tDCS has been found to improve language production in healthy and brain-injured speakers.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct-current stimulation (tDCS)
Description: Transcranial direct-current stimulation is a non-invasive brain stimulation method that can modify spontaneous cortical activity in targeted brain regions. Anodal tDCS delivered through a positively charged electrode has been found to increase cortical excitability in a targeted brain region. Application of tDCS has been found to improve language production in healthy and brain-injured speakers.
Study: NCT00409292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Taken orally daily for as long as the participant continues to receive a benefit.
Study: NCT01430065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: oral
Study: NCT04528758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rhodamine 6G
Description: Rhodamine 6G radio-pharmaceutical will be injected to determine myocardial blood flow

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rhodamine 6G
Description: Rhodamine 6G radio-pharmaceutical will be injected to determine myocardial blood flow
Study: NCT01918475

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Carbetocin 0.1 mg single dose is intravenously administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Carbetocin 0.1 mg single dose is intravenously administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 1ml of NaCl 0.9% is administered intravenously
Study: NCT03677856

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paravertebral blockade
Description: Type of anaesthesia
Study: NCT01918475

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 1ml of NaCl 0.9% is administered intravenously
Study: NCT03677856

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidural block
Description: Type of anaesthesia
Study: NCT01276080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: 10 mg tablets
Study: NCT04604457

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative care contacts primary care
Description: Palliative care specialist reaches out to primary care to recommend a palliative care consult. If the primary care provider agrees, he/she will write an order for a palliative care consult.
Study: NCT00715793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: In Part I patients will be treated on a standard 3+3 phase I dose-escalation design starting at 0.075 mg/kg until a decitabine dose level of 0.15 mg/kg is reached, or, in case unacceptable toxicities are observed, at the maximum tolerated dose (Phase II recommended dose). Decitabine will be administered at the specified dose level, intravenously, daily 5 days a week for the first 2 weeks of a 6-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide is available in 25 mg and 100 mg tablets that will be administered orally; doses will be rounded to the nearest 25 mg. Temozolomide will be administered orally at 75 mg/m2 daily for 4 weeks starting on week 2 of a 6-week cycle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Fine needle aspirates (FNA) and/or core biopsies of tumor samples will be obtained from consenting patients with accessible, evaluable disease, on days 1, 8, 15, and 29 of the first cycle and when patients go off study. Biopsies are optional in Phase I and required for all consenting subjects in Phase II.
Study: NCT01276080

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: 10 mg tablets
Study: NCT03623958

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Image guided Video-Assisted Thoracic Surgery (VATS) resection
Description: Image guided placement of a fiducial consisting of a needle directed placement of a T-Bar next to the target lesion in order to lead the surgeon to the lung region to be removed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Video-Assisted Thoracic Surgery
Description: Standard of Care Video-Assisted Thoracic Surgery (VATS) resection
Study: NCT03033797

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MoviLetrando
Description: Half of the participants will play two different levels of the Game MoviLetrando, two minutes each.
Study: NCT01824095

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary supplement
Study: NCT00719056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teicoplanin
Description: The selected dose was 10mg/kg and it was given intravenously by a catheter inserted under aseptic conditions in a forearm vein within 15 minutes; it was diluted in one 5% glucose solution of a 50 ml final volume
Study: NCT03033797

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MoveHero
Description: Half of the participants will play 2 minutes of the game MoveHero.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MoveHero
Description: Half of the participants will play 2 minutes of the game MoveHero.
Study: NCT04466163

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Schema Therapy and the Healthy Adult
Description: The protocol 'Schematherapy and the Healthy Adult' (ST-HA, Broersen \& Claassen, 2019) is a direct intervention meant to strengthen patients' healthy adult functioning by developing compassion and care for well-being in the face of (childhood) adversity.
Study: NCT00719407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erythropoietin
Description: 250 U/kg/dose x 6 doses (n=3); 500 U/kg/dose x 6 doses (n=6); 1,000 U/kg/dose x 6 doses (n=7) 2,500 U/kg/dose x 6 doses (n=8)
Study: NCT03952793

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: extended biopsy
Description: Additional sample are performed during a biopsy to provide tumor tissues for the organoid technique development
Study: NCT02165111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onabotulinumtoxin A

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sterile saline solution
Study: NCT02806479

Intervention type: OTHER
Intervention: Observational: Arrhythmogenic Substrate

Intervention type: OTHER
Intervention: Observational: Arrhythmogenic Substrate
Study: NCT00094653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDX-010 (anti-CTLA4) monoclonal antibody
Description: 3mg/kg (intravenous \[iv\] infusion over 90 minutes), every 3 weeks for 4 doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MDX-010 (anti-CTLA4) monoclonal antibody
Description: 3mg/kg (intravenous \[iv\] infusion over 90 minutes), every 3 weeks for 4 doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MDX-1379 (gp100) Melanoma Peptide Vaccine
Description: 2mL (2 subcutaneous injections of 2 mL each, 1 to each thigh), every 3 weeks for 4 doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MDX-1379 (gp100) Melanoma Peptide Vaccine
Description: 2mL (2 subcutaneous injections of 2 mL each, 1 to each thigh), every 3 weeks for 4 doses.
Study: NCT01836094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue (USP grade, 280mg oral)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral, one time
Study: NCT01153685

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluviral®
Description: Intramuscular injection, one dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluviral®
Description: Intramuscular injection, one dose
Study: NCT00330551

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Risperidone
Description: Patients will be treated with oral risperidone daily, with the dosage determined by treating psychiatrist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone in Long-Acting Injectable Form (Consta)
Description: Participants will take a 25 mg dosage of injectable risperidone (Risperidone in Long-Acting Injectable Form (Consta)) once every 2 weeks. Dosage will be adjusted if needed.
Study: NCT04630522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: JMT103- 120 mg SC Q4W
Description: JMT103 is administered subcutaneously at a dose of 120 mg on day 1 of each 4-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: JMT103- 120 mg SC Q8W
Description: JMT103 is administered subcutaneously at a dose of 120 mg on day 1 of each 8-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: JMT103- 180 mg SC Q8W
Description: JMT103 is administered subcutaneously at a dose of 180 mg on day 1 of each 8-week cycle.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: Calcium Dietary Supplement: Vitamin D
Description: Calcium is given orally at a dose of 500 mg at least, once daily. Vitamin D is given orally at a dose of 400 IU at least, once daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: Calcium Dietary Supplement: Vitamin D
Description: Calcium is given orally at a dose of 500 mg at least, once daily. Vitamin D is given orally at a dose of 400 IU at least, once daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: Calcium Dietary Supplement: Vitamin D
Description: Calcium is given orally at a dose of 500 mg at least, once daily. Vitamin D is given orally at a dose of 400 IU at least, once daily.
Study: NCT00719056

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: β-lactams or ciprofloxacin
Description: Multiple doses for up to six consecutive days
Study: NCT04698707

Intervention type: OTHER
Intervention: Vascularized lymph node flap transfer
Description: Patients who have received VLNT as their primary treatment but with minimal improvement

Intervention type: OTHER
Intervention: Patients without prior lymphedema surgery
Description: Patients without prior lymphedema surgery
Study: NCT04707014

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: Rapid conversational hypnosis

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention-distracting techniques
Description: i-pad with movies, games and music
Study: NCT04466436

Intervention type: OTHER
Intervention: tryptophan
Description: measurement of tryptophan in serum

Intervention type: OTHER
Intervention: tryptophan
Description: measurement of tryptophan in serum
Study: NCT02130648

Intervention type: OTHER
Intervention: A sampling of blood
Description: A sampling of blood de 14 ml
Study: NCT04269031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2373 subcutaneous injection
Description: Randomised subjects will receive a single ascending dose of AZD2373 by SC injection (dose 1, dose 2, dose 3, dose 4, dose 5 and dose 6).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2373 subcutaneous injection
Description: Randomised subjects will receive a single ascending dose of AZD2373 by SC injection (dose 1, dose 2, dose 3, dose 4, dose 5 and dose 6).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2373 subcutaneous injection
Description: Randomised subjects will receive a single ascending dose of AZD2373 by SC injection (dose 1, dose 2, dose 3, dose 4, dose 5 and dose 6).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2373 subcutaneous injection
Description: Randomised subjects will receive a single ascending dose of AZD2373 by SC injection (dose 1, dose 2, dose 3, dose 4, dose 5 and dose 6).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2373 subcutaneous injection
Description: Randomised subjects will receive a single ascending dose of AZD2373 by SC injection (dose 1, dose 2, dose 3, dose 4, dose 5 and dose 6).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2373 subcutaneous injection
Description: Randomised subjects will receive a single ascending dose of AZD2373 by SC injection (dose 1, dose 2, dose 3, dose 4, dose 5 and dose 6).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Randomised subjects will receive a single ascending dose of placebo (saline solution) by SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Randomised subjects will receive a single ascending dose of placebo (saline solution) by SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Randomised subjects will receive a single ascending dose of placebo (saline solution) by SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Randomised subjects will receive a single ascending dose of placebo (saline solution) by SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Randomised subjects will receive a single ascending dose of placebo (saline solution) by SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Randomised subjects will receive a single ascending dose of placebo (saline solution) by SC injection.
Study: NCT03015207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0194-0499

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00447265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: 1.) Immune suppressant. 2.) Tumor necrosis factor (TNF) inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lupus Treatment- Standard of Care
Description: Individualized standard of care treatment for lupus with corticosteroids and with mycophenolate mofetil (MMF), mycophenolic acid, or azathioprine (AZA)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lupus Treatment- Standard of Care
Description: Individualized standard of care treatment for lupus with corticosteroids and with mycophenolate mofetil (MMF), mycophenolic acid, or azathioprine (AZA)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00056537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABR-217620
Description: Starting dose: 0.5 mcg/kg; subsequent doses: individual, based on pre-treatment level of anti-SEA/E-120, body weight, and toxicities observed in prior patients on study; IV; one bolus injection each day for 5 consecutive days; up to 3 cycles
Study: NCT02658578

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PNS
Description: Active PNS will be administered by 2 pairs of surface electrodes (cathode proximal). One pair will overly the median and ulnar nerves at the wrist, and the other pair will overly the radial nerve. Trains of electric stimulation will be delivered at 1 Hz by using isolation units connected to a square pulse stimulator. In sham PNS, the median, ulnar and radial nerves will not be actively stimulated.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PNS
Description: Active PNS will be administered by 2 pairs of surface electrodes (cathode proximal). One pair will overly the median and ulnar nerves at the wrist, and the other pair will overly the radial nerve. Trains of electric stimulation will be delivered at 1 Hz by using isolation units connected to a square pulse stimulator. In sham PNS, the median, ulnar and radial nerves will not be actively stimulated.
Study: NCT02978690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Solution for infusion
Study: NCT01557075

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin (High dose statin treatment)
Description: Patients will be randomly assigned to the type of statins. Randomization of statin therapy will be done 1:1 to one of two different statins on the web-based program~* Atorvastatin 40 mg daily for 12 months after randomization
Study: NCT01871597

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulmonary Artery Energy Seal
Description: Pulmonary artery energy seal devices such as: Ligasure, Harmonic scalpel, Enseal, Thunderbeat, Unipolar and Conventional bipolar Cautery, metal clip or Hem-o-lok clip will be used to seal the artery(ies)
Study: NCT04737499

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CASCADe
Description: Culturally tailored diabetes self-management and education sessions with mHealth integration
Study: NCT01384916

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: 2x weekly

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living Workshop
Description: 2x weekly